1. Trends in parthenolide research over the past two decades: A bibliometric analysis
   Jiye Liu et al, 2023, Heliyon CrossRef
2. The Emerging Potential of Parthenolide Nanoformulations in Tumor Therapy
   Tao An et al, 2022, Drug Design, Development and Therapy CrossRef
3. Terpenoids’ anti-cancer effects: focus on autophagy
   Chirine El-Baba et al, 2021, Apoptosis CrossRef
4. Plants as a Source of Anticancer Agents: From Bench to Bedside
   Wamidh H. Talib et al, 2022, Molecules CrossRef
5. Parthenolide inhibits the proliferation and migration of cervical cancer cells via FAK/GSK3β pathway
   Liru Huang et al, 2024, Cancer Chemotherapy and Pharmacology CrossRef
6. Microtubules as a target of antitumor drugs
   M. A. Dodokhova et al, 2022, South Russian Journal of Therapeutic Practice CrossRef
7. Generation of multicellular tumor spheroids with micro-well array for anticancer drug combination screening based on a valuable biomarker of hepatocellular carcinoma
   Qi Wang et al, 2022, Frontiers in Bioengineering and Biotechnology CrossRef
8. A metabolomics approach reveals metabolic disturbance of human cholangiocarcinoma cells after parthenolide treatment
   Yongping He et al, 2024, Journal of Ethnopharmacology CrossRef
9. Natural Anticancer Agents: Their Therapeutic Potential, Challenges and Promising Outcomes
   Savita Tauro et al, 2024, Current Medicinal Chemistry CrossRef
10. Chemotherapeutics
    Yuri N. Clement, 2024, Pharmacognosy CrossRef
11. First Discovery of Cholesterol-Lowering Activity of Parthenolide as NPC1L1 Inhibitor
    Wenjing Liu et al, 2022, Molecules CrossRef
12. Identification and validation of a ferroptosis-related signature for prediction of the prognosis and tumor microenvironment in patients with chromophobe renal cell carcinoma
    Shuai Liu et al, 2023, BMC Cancer CrossRef